Company Description
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States.
The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors.
The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets.
Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 62 |
| CEO | Dr. Eric E. Poma Ph.D. |
Contact Details
Address: 9301 Amberglen Blvd, Suite 100 Austin, Texas 78729 United States | |
| Phone | 512 896 1555 |
| Website | mtem.com |
Stock Details
| Ticker Symbol | MTEM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001183765 |
| CUSIP Number | 608550109 |
| ISIN Number | US6085502085 |
| Employer ID | 94-3409596 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Eric E. Poma Ph.D. | Chief Executive Officer, Chief Scientific Officer and Director |
| Jason S Kim | President, Chief Financial Officer, Treasurer and Principal Accounting Officer |
| Kristen Quigley B.A. | Chief Operating Officer |
| Dr. Grace Kim | Chief Strategy Officer and Head of IR |
| Dr. Joseph Phillips Ph.D. | Senior Vice President and Head of CMC Development |
| Dr. Maurizio Voi M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | 8-K | Current Report |
| Apr 2, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 29, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 29, 2024 | 10-K | Annual Report |
| Mar 29, 2024 | 8-K | Current Report |
| Mar 28, 2024 | 8-K | Current Report |
| Mar 15, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |